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Breathing easy with carbon monoxide
 
Ancient Greek philosophers extolled moderation in all things. On page 283, Minamoto and colleagues
show that carbon monoxide (CO) inhalation is no exception. In a mouse model of trachea transplantation, 
inhaled CO—in moderation—prevented the development of lethal obstructive airway disease.
CO gas is both a toxic air pollutant and a normal byproduct of cellular heme metabolism. Although 
CO is well-known for its role as an asphyxiant, recent studies have revealed its virtues, which include 
anti-inflammatory and anti-apoptotic effects on a variety of cell types. CO has also been shown to inhibit 
the rejection of xenogeneic heart transplants in rats.
Minamoto et al. now add to that list of virtues by showing that treating mice with low-dose inhaled 
CO reduced the T cell infiltration and airway obstruction that develops after allogeneic tracheal 
transplantation. The benefits of endogenous CO were evident based on comparisons with mice that 
received grafts lacking the CO-synthesizing enzyme hemoxygenase-1 
(Hmox-1), which developed more severe disease than mice that 
received wild-type grafts.
This group previously showed that the development of post-transplant 
airway obstruction requires the expression of inducible nitric oxide 
synthase (iNOS). They now find that CO counterbalances the production 
of nitric oxide by inhibiting the activation of the transcription factor 
NF-
 
 
 
B, which drives the expression of iNOS.
This came as a surprise to the authors, as most other known effects 
of CO depend on activation of the MAP kinase or cyclic GMP signaling 
pathways. Further experiments are required to determine how CO 
inhibits NF-
 
 
 
B activation. But in the meantime, these data suggest that 
increasing endogenous CO levels might be therapeutic in transplant 
patients who develop a lethal, and currently untreatable, complication 
of lung transplantation called obliterative bronchiolitis. 
Inhaled carbon monoxide reduces T cell (brown) invasion of the 
airways following allogeneic tracheal transplantation.
 
Clotting revisited
 
On page 271, Renné and colleagues show that the absence of
a clot-promoting protein in mice keeps arteries from clog-
ging with no risk of excessive bleeding. These data challenge the
decades-old belief that this protein—called factor XII (FXII)
or Hageman factor—has no impact on clotting in vivo.
Blood clotting depends on the sequential activation of
proteins, called clotting factors, that culminates in the pro-
duction of fibrin—the protein that forms the meshwork of
the clot. This process must be tightly regulated, as too little
clotting can lead to bleeding disorders and too much clotting
can lead to blood vessel blockage, which triggers strokes and
heart attacks.
Deficiencies in some blood clotting proteins, such as tissue
factor and factor VII, result in fatal bleeding disorders. But
deficiencies in FXII are not associated with abnormal bleeding,
and thus this factor has long been considered dispensable for
normal clotting.
Renné and colleagues now reexamine a role for this
clotting factor in FXII-deficient mice. As they had previously
reported (and similar to the situation in humans), these mice
developed no spontaneous bleeding disorders. However, the
FXII-deficient mice were less likely to develop blocked arteries
(thrombosis) in response to induced vessel injury. Thrombosis
formation was initiated normally in the FXII-deficient mice,
but the clots were unstable and detached from the vessel wall
before they could grow large enough to impede blood flow,
suggesting that FXII is required not to initiate, but rather to
propagate, the clotting reaction.
Consistent with these findings, elevated plasma levels of
FXII in humans have been associated with increased coro-
nary artery disease, and lower levels with protection. Thus
the authors suggest that drugs that inhibit FXII might be
useful in treating heart disease without increasing the risk of
spontaneous bleeding. FXII-driven fibrin formation thus
appears to be essential for pathological thrombus formation.
The beneficial effects of this pathway, however, remain
mysterious. 
Vessel-blocking thrombus formation (white) in damaged mesenteric ves-
sels is prevented in the absence of coagulation factor XII (bottom panels).
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